Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
162.31
-5.88 (-3.50%)
At close: Feb 21, 2025, 4:00 PM
157.90
-4.41 (-2.72%)
After-hours: Feb 21, 2025, 6:19 PM EST
Natera Revenue
Natera had revenue of $439.76M in the quarter ending September 30, 2024, with 63.90% growth. This brings the company's revenue in the last twelve months to $1.53B, up 54.94% year-over-year. In the year 2023, Natera had annual revenue of $1.08B with 31.99% growth.
Revenue (ttm)
$1.53B
Revenue Growth
+54.94%
P/S Ratio
12.89
Revenue / Employee
$465,216
Employees
3,293
Market Cap
21.43B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.08B | 262.35M | 31.99% |
Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
Dec 31, 2020 | 391.01M | 88.68M | 29.33% |
Dec 31, 2019 | 302.33M | 44.67M | 17.34% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
NTRA News
- 4 days ago - Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025 - Business Wire
- 12 days ago - NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma - Business Wire
- 19 days ago - Natera Announces National Commercial Coverage for its Fetal RhD NIPT - Business Wire
- 27 days ago - Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer - Business Wire
- 4 weeks ago - Natera to Present New Data at the 2025 ASCO GI Symposium - Business Wire
- 5 weeks ago - Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year - Business Wire
- 5 weeks ago - Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection - Business Wire
- 5 weeks ago - Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024 - Business Wire